Back to search

Enedra Therapeutics Limited

13433538

active
Private Limited Company
england wales
Companies House
Health Score
90 / 100

Healthy

30/30
Filing
20/30
Financial
40/40
Risk

No risk factors detected.

Details

SALISBURY HOUSE, CAMBRIDGE, CB1 2LA
Incorporated 02/06/2021

Compliance

Last accounts

31/07/2025

total exemption full

Next accounts due

30/04/2027

On track

Confirmation statement

Last: 01/06/2025

Due 15/06/2026

On track

Industry

72190
Other research and experimental development on natural sciences and engineering

Officers

Mr Andreas Ballis

director · Since 02/06/2021

DIRECTOR

GREEK · UNITED KINGDOM · Age 47

Ms Tanya Marie Moore

director · Since 15/10/2021

SENIOR BUSINESS DEVELOPMENT EXECUTIVE

BRITISH · UNITED KINGDOM · Age 51

Also on 1 other board

Mr Keith Stuart Blundy

director · Since 11/04/2023

CONSULTANT

BRITISH · ENGLAND · Age 66

Also on 1 other board

Patrick Christian Maurice Chaltin

director · Since 06/11/2024

MANAGING DIRECTOR

BELGIAN · BELGIUM · Age 51

Dr Adrian Paul Ibrahim

director · Since 04/09/2025

BIOPHARMA EXECUTIVE

BRITISH · ENGLAND · Age 55

Also on 1 other board

Persons with Significant Control

Mr Andreas Ballis

50–75% shares
50–75% votes
Appoint directors

Greek · United Kingdom · Age 47

Salisbury House, Station Road, Cambridge, CB1 2LA

Notified 02/06/2021

Former PSCs

Alexander Paul Gutteridge

Ceased 04/03/2022

CompanyRankvs 826+ SIC 72190 peers
77

Financial strength90th percentile among SIC peers · 23/25
Employees90th percentile among SIC peers · 14/15
LiquidityCurrent ratio 20.23× · 20/20
Longevity5 years trading (max 15) · 5/15
Filing complianceAll filings up to date · 15/15
Show leaderboard
How is this score calculated?
Financial strength23/25 pts

Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.

Employees14/15 pts

Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.

Liquidity20/20 pts

Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.

Longevity5/15 pts

One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.

Filing compliance15/15 pts

Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.

Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.

Key FinancialsYear ending 31/07/2025

Net Worth

£388k

Balance sheet strength

Cash

£37k

Cash in the bank

Net Current Assets

£388k

Working capital

Current Assets

£408k

Current Liabilities

£20k

Fixed Assets

£638

Debtors

£371k

6avg. employees+2

People Costs(2024)

Wages & salaries£38k
NI contributions£3k

Balance Sheet

Assets less current liabilities£388k
Prepared with Caseware UK (AP4) 2024.0.164

EstimatesDerived

YearCurrent RatioImplied Profit
202520.23+£334k
20241.08+£149k
20230.51-£70k
20222.15

Derived from filed accounts. Not audited figures.